The UK government has announced a trade agreement with the USA. The UK-US Economic Prosperity Deal was agreed on Thursday May ...

Oculis Holding (Nasdaq: OCS) reported a net loss of $36 million for the first quarter of 2025, more than double the loss in ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, ...

Genmab (Nasdaq: GMAB) posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties ...

Belgium’s largest drugmaker UCB (Euronext: UCB) today revealed that it has received approval from Japan’s Pharmaceuticals and ...

Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug ...

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) ...

UK pharma major GSK (LSE: GSK) has unveiled full Phase III data showing its experimental drug linerixibat significantly ...

A preclinical-stage biotech company based in Italy, developing small molecule therapeutics that induce targeted protein ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

UK pharma major AstraZeneca (LSE: AZN) has suffered a setback in its legal fight to block the US government's efforts to lower prescription drug prices, after a federal appeals court dismissed its ...